Literature DB >> 31976147

A Report of a Novel Pathogenic Variant in a Family with Buschke-Ollendorf Syndrome.

Angita Jain1, Pavalan Selvam1, Herjot Atwal1, Paldeep S Atwal1.   

Abstract

Buschke-Ollendorf Syndrome (BOS) is a benign autosomal dominant disorder caused by pathogenic mutations in LEMD3 . Here, we describe a family diagnosed to have varied phenotypes associated with BOS. Single gene testing of LEMD3 detected a heterozygous frameshift pathogenic variant in both the affected family members. Besides the phenotypic description, this report highlights the need for a comprehensive evaluation in connective tissue disorders and the importance of genotype-phenotype correlation in BOS. © Thieme Medical Publishers.

Entities:  

Keywords:  LEMD3; collagenoma; familial Buschke–Ollendorf syndrome; osteopoikilosis

Year:  2019        PMID: 31976147      PMCID: PMC6976315          DOI: 10.1055/s-0039-1694767

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  10 in total

1.  Familial cutaneous collagenomas resulting from a novel mutation in LEMD3.

Authors:  D Hershkovitz; B Amitai; D B Amitai; E Sprecher
Journal:  Br J Dermatol       Date:  2007-02       Impact factor: 9.302

2.  DOG 1.0: illustrator of protein domain structures.

Authors:  Jian Ren; Longping Wen; Xinjiao Gao; Changjiang Jin; Yu Xue; Xuebiao Yao
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

Review 3.  Identification of a novel LEMD3 Y871X mutation in a three-generation family with osteopoikilosis and review of the literature.

Authors:  Q Zhang; Z H Mo; C S Dong; F Yang; Y H Xie; P Jin
Journal:  J Endocrinol Invest       Date:  2015-12-22       Impact factor: 4.256

4.  MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor-beta signaling.

Authors:  Feng Lin; Juliet M Morrison; Wei Wu; Howard J Worman
Journal:  Hum Mol Genet       Date:  2004-12-15       Impact factor: 6.150

5.  Buschke-Ollendorff syndrome associated with elevated elastin production by affected skin fibroblasts in culture.

Authors:  M G Giro; M Duvic; L T Smith; R Kennedy; R Rapini; F C Arnett; J M Davidson
Journal:  J Invest Dermatol       Date:  1992-08       Impact factor: 8.551

6.  Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis.

Authors:  Jan Hellemans; Olena Preobrazhenska; Andy Willaert; Philippe Debeer; Peter C M Verdonk; Teresa Costa; Katrien Janssens; Bjorn Menten; Nadine Van Roy; Stefan J T Vermeulen; Ravi Savarirayan; Wim Van Hul; Filip Vanhoenacker; Danny Huylebroeck; Anne De Paepe; Jean-Marie Naeyaert; Jo Vandesompele; Frank Speleman; Kristin Verschueren; Paul J Coucke; Geert R Mortier
Journal:  Nat Genet       Date:  2004-10-17       Impact factor: 38.330

7.  LEM domain-containing protein 3 antagonizes TGFβ-SMAD2/3 signaling in a stiffness-dependent manner in both the nucleus and cytosol.

Authors:  Dwight M Chambers; Leandro Moretti; Jennifer J Zhang; Spencer W Cooper; Davis M Chambers; Philip J Santangelo; Thomas H Barker
Journal:  J Biol Chem       Date:  2018-08-14       Impact factor: 5.157

8.  Eruptive collagenoma: a rarely reported entity in Indian literature.

Authors:  Prachi Barad; Joycelin Fernandes; Pankaj Shukla
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

10.  Mutation in LEMD3 (Man1) Associated with Osteopoikilosis and Late-Onset Generalized Morphea: A New Buschke-Ollendorf Syndrome Variant.

Authors:  Benjamin Korman; Jun Wei; Anne Laumann; Polly Ferguson; John Varga
Journal:  Case Rep Dermatol Med       Date:  2016-06-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.